IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519790-19-00

Enrollment

Registered

2025-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

Brief summary

Safety associated with the infusion of HSP-CAR19M cells. In the expansion phase: evaluation of the safety and efficacy of HSP-CAR19M cell administration.

Interventions

DRUGLevact 2

DRUG5 mg/ml

DRUGpolvo para concentrado para solución para perfusión.

DRUGBeneflur10 mg comprimidos recubiertos con película

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGGenoxal 200 mg polvo para solución inyectable y para perfusión

DRUGHSP-CAR19M

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety associated with the infusion of HSP-CAR19M cells. In the expansion phase: evaluation of the safety and efficacy of HSP-CAR19M cell administration.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026